Book a Meeting

Non-Fucosylated Anti-Human CD39 (BY40) Therapeutic Antibody (CAT#: BioBet-664ZP) Datasheet

Target
CD39
Isotype
IgG
Description
ADCC-Enhanced anti-CD39 (by Creative Biolabs' Afuco™ technology platform.40) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD39 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD39
Full Name
ectonucleoside triphosphate diphosphohydrolase 1
Background
CD38 is a novel multifunctional ectoenzyme widely expressed in cells and tissues especially in leukocytes. CD38 also functions in cell adhesion, signal transduction and calcium signaling.
Alternative Names
ENTPD1; ectonucleoside triphosphate diphosphohydrolase 1; CD39; SPG64; ATPDase; NTPDase-1; NTPDase 1; CD39 antigen; ecto-apyrase; ecto-ATPase 1; ecto-ATPDase 1; ecto-ATP diphosphohydrolase 1; lymphoid cell activation antigen
Gene ID
953
UniProt ID
Q5ZPR3
Cellular Localization
Extracellular region or secreted, Endoplasmic reticulum
Involvement in Disease
Diseases associated with ENTPD1 include Spastic Paraplegia 64, Autosomal Recessive and Paraplegia.
Related Pathways
Its related pathways are ATP/ITP metabolism and Metabolism of nucleotides.
Function
In the nervous system, it can hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. It is also possible to prevent platelet aggregation by hydrolyzing platelet-activated ADP. Hydrolysis of ATP and ADP have the same effect.
Post-translational modifications
The N-terminus is blocked. Palmitoylated in the N-terminal part.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BY40
Host
Mouse
Species Reactivity
Human
Description
The antibody against human CD39 can be used for the treatment or prevention of cancers and infectious diseases.
Indication
Cancer

Cancer

Related Products

Non-Fucosylated Anti-Human CD39 (CNCM-I-3889) Therapeutic Antibody (CAT#: BioBet-665ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany